Issues
-
Cover Image
Cover Image
About the Cover
Gastric cancer is a common cancer that affects millions of people worldwide. The accurate staging of this cancer is a critical first step upon which a patient's prognosis and treatment options are based. The conventional staging grid is based on three factors: tumor size, lymphnode involvement, and metastasis (TNM staging). However, the variablility of outcomes for patients within the same TNM stage strongly suggests that other key factors need to be included to obtain a more useful classification. Wen et al. examined immunological factors and scored them according to their associations with disease progression. Using only four immune parameters, they identified patients who were in the same stage according to their TNM classification to be at low, medium, or high risk of progressive disease based on their “immunoscore.” Read more in this issue of Cancer Immunology Research starting on page 524. The micrograph, from Fig. 5, is a slice of gastric tumor infiltrated by multiple immune cell types in various activation states. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
Highlights from the Literature
Priority Brief
Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity
Research Articles
A Four-Factor Immunoscore System That Predicts Clinical Outcome for Stage II/III Gastric Cancer
Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib
Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer
Antitumor Effects of Epidrug/IFNα Combination Driven by Modulated Gene Signatures in Both Colorectal Cancer and Dendritic Cells
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.